Therapeutics case studies

ICON was awarded two early development cancer immunotherapy studies from a biotherapeutic company for a potentially ground¬breaking autologous cellular therapy in the treatment of two tumour types.

Sponsor proposed a randomized, open-label, multi-centre, parallel-group study comparing the safety and efficacy of STUDY DRUG with Novolog in type 1 diabetes (T1D) patients.

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

ICON was contracted to conduct an early-phase clinical trial in Huntington’s disease across 12 countries and 53 sites.

ICON provided full-service support to a large biotech company in two global Phase 3 trials for a gene therapy product treating spinal muscular atrophy (SMA), a rare but serious condition causing muscle wasting and weakness.

Clinical trial participation exposes rare disease participants to significant pressure financially, logistically and psychologically, and these incremental pressures can negatively impact a patient’s ability or willingness to enrol or remain in a clinical trial.

In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.

There are no specific pharmaceutical therapies available for TBI. Since 2001, ICON staff have participated in managing mult national TBI trials with several drugs including endopeptidase inhibitor and endothelin converting enzyme inhibitors, involving more than 1,000 TBI patients.

ICON exceeded recruitment objectives within the initial recruitment timelines during COVID-19 pandemic.

A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early-phase trials.

ICON partnered with a drug development sponsor to conduct a global programme for Multiple sclerosis (MS) studies in over 2,200 patients.

ICON was engaged to support phase 2 study in patients with heartfailure and impaired systolic function. ICON’s proactive approach ensured the successful delivery of this complex study and enabled the client to make key strategic program decisions to advance their larger phase 2 trial.